Yıl: 2020 Cilt: 55 Sayı: 1 Sayfa Aralığı: 30 - 38 Metin Dili: İngilizce DOI: 10.14744/TurkPediatriArs.2019.60938 İndeks Tarihi: 19-08-2020

Evaluation of potential drug-drug interactions in a pediatric population

Öz:
Aim: A large number of medications are prescribed in pediatricclinics and this leads to the development of drug–drug interactions(DDI) that may complicate the course of the disease. The aim of thestudy was to identify the prevalence of potential drug–drug interactions, to categorize main drug classes involved in severe drug–druginteractions and to highlight clinically relevant DDIs in a pediatricpopulation.Material and Methods: A total of 1500 prescriptions during the12-month study period were retrospectively reviewed; 510 prescriptions that comprised two or more drugs were included in study.The presence of potential drug–drug interactions was identifiedby using the Lexi-Interact database and categorized according toseverity: A (unknown), B (minor), C (moderate), D (major), and X(contraindicated).Results: There were 1498 drugs in 510 prescriptions; 253 of these(49.6%) included 2 drugs, 228 (44.7%) included 3–4 drugs, and 29(5.6%) included ≥5 drugs. A total of 634 (42%) potential drug–druginteractions were idenfied. Among those, 271 (42.7%) were categorized as A, 284 (44.8%) as B, 53 (8.4%) as C, and 26 (4.1%) as D. Therewas no potential risk for X interaction. Anti-infectives (36%) werethe most commonly prescribed drug classes involved in C and/orD categories. Clarithromycin was the most commonly interactingagent that interfered with budesonide.Conclusion: It is noteworthy that a significant number of drugscausing potential drug–drug interactions are prescribed togetherin pediatric clinics. Increasing the awareness of physicians on thisissue will prevent potential complications and ensure patient safety.
Anahtar Kelime:

Çocuk kliniğinde potansiyel ilaç-ilaç etkileşimlerinin değerlendirilmesi

Öz:
Amaç: Çocuk kliniklerinde çok sayıda ilaç reçete edilmektedir ve bu durum hastalığın seyrini kötüleştirebilecek ilaç-ilaç etkileşimlerinin oluşmasına neden olabilmektedir. Bu çalışmanın amacı, potansiyel ilaç-ilaç etkileşimlerinin yaygınlığını ve ciddi etkileşime giren başlıca ilaç gruplarını belirlemek ve çocuk yaş grubunda klinik olarak önemli ilaç-ilaç etkileşimlerini vurgulamaktır. Gereç ve Yöntemler: 12 aylık çalışma döneminde toplam 1 500 reçete geriye dönük olarak incelendi; bunlar içerisinden iki ya da daha fazla ilaç içeren 510 reçete çalışmaya alındı. Potansiyel ilaç-ilaç etkileşimlerinin varlığı, Lexi-Interact veritabanı kullanılarak belirlendi ve ciddiyetine göre sınıflandı: A (bilinmeyen), B (minor), C (orta), D (major) ve X (kontrendike). Bulgular: 510 reçetede toplam 1498 ilaç vardı; bunların 253’ü (%49,6) 2 ilaç, 228’i (%44,7) 3–4 ilaç ve 29’u (%5,6) ≥5 ilaç içermekte idi. Toplam 634 (%42) potansiyel ilaç-ilaç etkileşimi belirlendi. Bunlardan 271’i (%42,7) A, 284’ü (%44,8) B, 53’ü (%8,4) C ve 26’sı (%4,1) D grubuetkileşim olarak sınıflandırıldı. X etkileşimi içeren risk saptanmadı. C ya/ya da D kategorisinde en yaygın reçete edilen ilaç grubu anti-infektifler (%36) idi. Klaritromisin, budesonide ile etkileşen ve en sık etkileşime giren ilaç idi. Çıkarımlar: Çocuk kliniklerinde potansiyel ilaç-ilaç etkileşimlerine neden olan ilaçların sıklıkla birlikte reçete edilmesi dikkat çekicidir. Klinisyenlerin bu konudaki farkındalığının arttırılması olası komplikasyonları önleyecek ve hasta güvenliğini artıracaktır.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
1
0
  • 1. Salem F, Rostami-Hodjegan A, Johnson TN. Do children have the same vulnerability to metabolic drug–drug interactions as adults? A critical analysis of the literature. J Clin Pharmacol 2013; 53: 559–66. [CrossRef ]
  • 2. Martinbiancho J, Zuckermann J, Dos Santos L, Silva MM. Profile of drug interactions in hospitalized children. Pharm Pract (Granada) 2007; 5: 157–61. [CrossRef ]
  • 3. Papadopoulos J, Smithburger PL. Common drug interactions leading to adverse drug events in the intensive care unit: management and pharmacokinetic considerations. Crit Care Med 2010; 38: S126–35. [CrossRef ]
  • 4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200–5. [CrossRef ]
  • 5. Salerno SN, Burckart GJ, Huang SM, Gonzalez D. Pediatric Drug-Drug Interaction Studies: Barriers and Opportunities. Clin Pharmacol Ther 2019; 105: 1067–70. [CrossRef ]
  • 6. Feinstein J, Dai D, Zhong W, Freedman J, Feudtner C. Potential drug-drug interactions in infant, child, and adolescent patients in children’s hospitals. Pediatrics 2015; 135: e99–e108. [CrossRef ]
  • 7. Morales-Ríos O, Jasso-Gutiérrez L, Reyes-López A, Garduño-Espinosa J, Muñoz-Hernández O. Potential drugdrug interactions and their risk factors in pediatric patients admitted to the emergency department of a tertiary care hospital in Mexico. PLoS One 2018; 13: e0190882.
  • 8. WHO Collaborating Centre. ATC/DDD Index 2020. Available from: https://www.whocc.no/atc_ddd_index/.
  • 9. Lexicomp. Lexi-Interact Online App. Available from https://www.uptodate.com/contents/search (accessed August 2018).
  • 10. World Health Organization. Action Programme onEssential Drugs. Model guide to good prescribing. Geneva: WHO; 1991.
  • 11. Andrade PH, Santos AD, Souza CA, Lobo IM, da Silva WB. Risk factors for adverse drug reactions in pediatric inpatients: a systematic review. Ther Adv Drug Saf 2017; 8: 199−210. [CrossRef ]
  • 12. Dai D, Feinstein JA, Morrison W, Zuppa AF, Feudtner C. Epidemiology of Polypharmacy and Potential DrugDrug Interactions Among Pediatric Patients in ICUs of U.S. Children’s Hospitals. Pediatr Crit Care Med 2016; 17: e218–28. [CrossRef ]
  • 13. Masukawa YM, Veríssimo GB, Vianello Richtzenhain MH, Alessandra L. Drug interactions in children with respiratory diseases in the pediatric unit of a teaching hospital in Brazil. Rev Cubana Pediatr 2016; 88: 166−81.
  • 14. Langerová P, Prokeš M, Konvalinka M, Fürstová J, Urbánek K. Incidence of potential drug interactions in medication prescriptions for children and adolescents in the University Hospital Olomouc, Czech Republic. Eur J Pediatr 2013; 172: 631–8. [CrossRef ]
  • 15. Hassanzad M, Arenas-Lopez S, Baniasadi S. Potential Drug-Drug Interactions Among Critically Ill Pediatric Patients in a Tertiary Pulmonary Center. J Clin Pharmacol 2018; 58: 221–7. [CrossRef ]
  • 16. Womer J, Zhong W, Kraemer FW, et al. Variation of opioid use in pediatric inpatients across hospitals in the U.S. J Pain Symptom Manage 2014; 48: 903–14. [CrossRef ]
  • 17. Baniasadi S, Fahimi F, Shalviri G. Developing an adverse drug reaction reporting system at a teaching hospital. Basic Clin Pharmacol Toxicol 2008; 102: 408–11. [CrossRef ]
  • 18. Meiners MM, Bergsten-Mendes G. Drug prescription for hospitalized pediatric patients: how can the quality be evaluated? [Article in Portuquese]. Rev Assoc Med Bras 1992; 47: 332-7. [CrossRef ]
  • 19. Baxter K. Stockley’s drug interactions. 8th ed. London: Pharmaceutical Press; 2008.p. 2−11.
  • 20. Pereira JM, Paiva JA. Antimicrobial drug interactions in the critically ill patients. Curr Clin Pharmacol 2013; 8: 25–38. [CrossRef ]
  • 21. Del Rosso JQ. Oral antibiotic drug interactions of clinical significance to dermatologists. Dermatol Clin 2009; 27: 91–4. [CrossRef ]
  • 22. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med 2008; 19: 413–20. [CrossRef ]
  • 23. Magro L, Conforti A, Del Zotti F, et al. Identification of severe potential drug-drug interactions using an Italian general-practitioner database. Eur J Clin Pharmacol 2008; 64: 303–9. [CrossRef ]
  • 24. Ganeva M, Gancheva T, Troeva J, Kiriyak N, Hristakieva E. Clinical relevance of drug-drug interactions in hospitalized dermatology patients. Adv Clin Exp Med 2013; 22: 555–63.
  • 25. Hansten PD. Drug interaction management. Pharm World Sci 2003; 25: 94–7. [CrossRef ]
  • 26. Moore N. The role of the clinical pharmacologist in the management of adverse drug reactions. Drug Saf 2001; 24: 1–7. [CrossRef ]
  • 27. Fernandez E, Perez R, Hernandez A, Tejada P, Arteta M, Ramos JT. Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults. Pharmaceutics 2011; 3: 53–72. [CrossRef ]
  • 28. Kheshti R, Aalipour M, Namazi S. A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract 2016; 5: 257–63. [CrossRef ]
APA BEBİTOĞLU B, OGUZ E, Nuhoglu C, DALKILIÇ A, ÇİRTLİK P, TEMEL F, HODZİC A (2020). Evaluation of potential drug-drug interactions in a pediatric population. , 30 - 38. 10.14744/TurkPediatriArs.2019.60938
Chicago BEBİTOĞLU Berna Terzioğlu,OGUZ ELIF,Nuhoglu Cagatay,DALKILIÇ Ayşe Ela Kurtdan,ÇİRTLİK Pelin,TEMEL Fatime,HODZİC Ajla Evaluation of potential drug-drug interactions in a pediatric population. (2020): 30 - 38. 10.14744/TurkPediatriArs.2019.60938
MLA BEBİTOĞLU Berna Terzioğlu,OGUZ ELIF,Nuhoglu Cagatay,DALKILIÇ Ayşe Ela Kurtdan,ÇİRTLİK Pelin,TEMEL Fatime,HODZİC Ajla Evaluation of potential drug-drug interactions in a pediatric population. , 2020, ss.30 - 38. 10.14744/TurkPediatriArs.2019.60938
AMA BEBİTOĞLU B,OGUZ E,Nuhoglu C,DALKILIÇ A,ÇİRTLİK P,TEMEL F,HODZİC A Evaluation of potential drug-drug interactions in a pediatric population. . 2020; 30 - 38. 10.14744/TurkPediatriArs.2019.60938
Vancouver BEBİTOĞLU B,OGUZ E,Nuhoglu C,DALKILIÇ A,ÇİRTLİK P,TEMEL F,HODZİC A Evaluation of potential drug-drug interactions in a pediatric population. . 2020; 30 - 38. 10.14744/TurkPediatriArs.2019.60938
IEEE BEBİTOĞLU B,OGUZ E,Nuhoglu C,DALKILIÇ A,ÇİRTLİK P,TEMEL F,HODZİC A "Evaluation of potential drug-drug interactions in a pediatric population." , ss.30 - 38, 2020. 10.14744/TurkPediatriArs.2019.60938
ISNAD BEBİTOĞLU, Berna Terzioğlu vd. "Evaluation of potential drug-drug interactions in a pediatric population". (2020), 30-38. https://doi.org/10.14744/TurkPediatriArs.2019.60938
APA BEBİTOĞLU B, OGUZ E, Nuhoglu C, DALKILIÇ A, ÇİRTLİK P, TEMEL F, HODZİC A (2020). Evaluation of potential drug-drug interactions in a pediatric population. Türk Pediatri Arşivi, 55(1), 30 - 38. 10.14744/TurkPediatriArs.2019.60938
Chicago BEBİTOĞLU Berna Terzioğlu,OGUZ ELIF,Nuhoglu Cagatay,DALKILIÇ Ayşe Ela Kurtdan,ÇİRTLİK Pelin,TEMEL Fatime,HODZİC Ajla Evaluation of potential drug-drug interactions in a pediatric population. Türk Pediatri Arşivi 55, no.1 (2020): 30 - 38. 10.14744/TurkPediatriArs.2019.60938
MLA BEBİTOĞLU Berna Terzioğlu,OGUZ ELIF,Nuhoglu Cagatay,DALKILIÇ Ayşe Ela Kurtdan,ÇİRTLİK Pelin,TEMEL Fatime,HODZİC Ajla Evaluation of potential drug-drug interactions in a pediatric population. Türk Pediatri Arşivi, vol.55, no.1, 2020, ss.30 - 38. 10.14744/TurkPediatriArs.2019.60938
AMA BEBİTOĞLU B,OGUZ E,Nuhoglu C,DALKILIÇ A,ÇİRTLİK P,TEMEL F,HODZİC A Evaluation of potential drug-drug interactions in a pediatric population. Türk Pediatri Arşivi. 2020; 55(1): 30 - 38. 10.14744/TurkPediatriArs.2019.60938
Vancouver BEBİTOĞLU B,OGUZ E,Nuhoglu C,DALKILIÇ A,ÇİRTLİK P,TEMEL F,HODZİC A Evaluation of potential drug-drug interactions in a pediatric population. Türk Pediatri Arşivi. 2020; 55(1): 30 - 38. 10.14744/TurkPediatriArs.2019.60938
IEEE BEBİTOĞLU B,OGUZ E,Nuhoglu C,DALKILIÇ A,ÇİRTLİK P,TEMEL F,HODZİC A "Evaluation of potential drug-drug interactions in a pediatric population." Türk Pediatri Arşivi, 55, ss.30 - 38, 2020. 10.14744/TurkPediatriArs.2019.60938
ISNAD BEBİTOĞLU, Berna Terzioğlu vd. "Evaluation of potential drug-drug interactions in a pediatric population". Türk Pediatri Arşivi 55/1 (2020), 30-38. https://doi.org/10.14744/TurkPediatriArs.2019.60938